Torrent Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2022.
The company has reported fall of 20.79% in its net profit at Rs 221 crore for the quarter under review as compared to Rs 279 crore for the same quarter in the previous year. Total income of the company increased by 10.52% at Rs 1723 crore for Q4FY22 as compared Rs 1559 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported net loss at Rs 118 crore for the quarter under review as compared to net profit of Rs 324 crore for the same quarter in the previous year. However, total income of the company increased by 10.68% at Rs 2187 crore for Q4FY22 as compared Rs 1976 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported fall of 12.92% in its net profit at Rs 991 crore as compared to Rs 1138 crore for the previous year. However, total income of the company increased by 5.74% at Rs 6946 crore for year under review as compared to Rs 6569 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported fall of 37.94% in its net profit at Rs 777 crore as compared to Rs 1252 crore for the previous year. However, total income of the company increased by 7.98% at Rs 8705 crore for year under review as compared to Rs 8062 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |